These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7515211)

  • 21. Prostate cancer in the late 1990s: hormone refractory disease options.
    Moul JW; Lipo DR
    Urol Nurs; 1999 Jun; 19(2):125-31; quiz 132-3. PubMed ID: 10633763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer update: 2007.
    Lin AM; Small EJ
    Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
    Oliver RT; Gallagher CJ
    Cancer Surv; 1995; 23():191-207. PubMed ID: 7621458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes.
    Berg A; Dahl AA; Bruland ØS; Bjøro T; Aanensen MS; Fosså SD
    Prostate Cancer Prostatic Dis; 2009; 12(3):269-76. PubMed ID: 19290019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current controversies in the treatment of high-risk prostate cancer.
    Mitchell RE; Chang SS
    Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Canadian trials in hormonally resistant prostate cancer.
    Moore MJ; Tannock IF
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):15-9. PubMed ID: 8996579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
    Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
    Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic prostate cancer progressing despite androgen suppression: two main options.
    Prescrire Int; 2013 Mar; 22(136):77. PubMed ID: 23593700
    [No Abstract]   [Full Text] [Related]  

  • 32. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment possibilities for patients with advanced prostate cancer].
    Gillessen S; Strasser F
    Ther Umsch; 2006 Feb; 63(2):157-62. PubMed ID: 16514969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of advanced prostate cancer.
    Auclerc G; Antoine EC; Cajfinger F; Brunet-Pommeyrol A; Agazia C; Khayat D
    Oncologist; 2000; 5(1):36-44. PubMed ID: 10706648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.
    Crawford ED; Kozlowski JM; Debruyne FM; Fair WR; Logothetis CJ; Balmer C; Robinson RG; Porter AT; Kirk D
    Urology; 1994 Oct; 44(4):481-5. PubMed ID: 7524233
    [No Abstract]   [Full Text] [Related]  

  • 36. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
    Johannsen M; Wilke K; Schnorr D; Loening SA
    Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hormone-resistant prostate cancer].
    Lilleby W; Hernes E; Waehre H; Raabe N; Fosså SD
    Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2798-801. PubMed ID: 17086220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of relapsed prostatic carcinoma following primary treatment.
    Newling DW
    Eur Urol; 1993; 24 Suppl 2():87-93. PubMed ID: 7505234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line treatment of metastatic prostatic carcinoma.
    Newling DW
    Urol Res; 1997; 25 Suppl 2():S73-8. PubMed ID: 9144891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palliative care in castrate-resistant prostate cancer.
    Rabow MW; Lee MX
    Urol Clin North Am; 2012 Nov; 39(4):491-503. PubMed ID: 23084526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.